Cardiovascular management of marfan syndrome in the young
- Angela M. Sharkey MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Marfan syndrome is an autosomal-dominant disorder of connective tissue resulting from a mutation in the fibrillin gene. Manifestations of the disorder primarily affect the skeletal, cardiovascular, and ocular systems. The phenotypic manifestations of this disorder can be quite variable. The major cause of morbidity and mortality in this patient population is the cardiovascular manifestations of the disorder: aortic root dilation and dissection. Individuals with this disorder are at risk for catastrophic cardiovascular events, most often as a result of aortic dissection. Although the incidence of dissection in childhood is exceedingly low, the background of a progressively dilating aortic root appears to be the major factor contributing to this risk in adulthood. Therefore, it is beneficial to identify affected individuals as early as possible to institute lifestyle changes and medical therapy in an effort to enhance their long-term outcome. Familial screening, once a case has been identified, and consideration of genetic screening of an affected family may also be helpful. Medical therapy with β blockers, calcium channel blockers, and/or angiotensin inhibitors has been shown to be somewhat effective in slowing the rate of growth of the aorta. Exciting new data suggest that angiotensin II receptor antagonists may provide an even greater degree of protection from aortic dilatation in this population. Despite medical therapy, patients with Marfan syndrome do have progressive dilatation of their aortic root. The risk of aortic dissection increases with increasing size of the aorta. Prophylactic surgical techniques have been successful in reducing the morbidity and mortality associated with aortic dissection, resulting in a longer average life span in this patient population.
- Pyeritz RE: Marfan syndrome and other disorders of fibrillin. In Principles and Practice of Medical Genetics, edn 3. Edited by Rimoin DL, et al. New York: Churchill Livingstone; 1997:1027–1066.
- Dietz HC, Cutting GR, Pyeritz RE, et al: Defects in the fibrillin gene cause the Marfan syndrome: linkage evidence and identification of a missense mutation. Nature 1991, 352:337–339. CrossRef
- Collod-Beroud G: Marfan database. Nucleic Acids Res 1998, 26:229–233. CrossRef
- Murdoch JL, Walker BA, Halpern BL, et al: Life expectancy and causes of death in the Marfan Syndrome. N Engl J Med 1972, 286:804–808. CrossRef
- Shores J, Berger KR, Murphy EA, et al: Progression of aortic dilatation and the benefit of long-term betaadrenergic blockade in Marfan’s syndrome. N Engl J Med 1994, 330:1335–1341. CrossRef
- Pyreitz RE: Effectiveness of beta-adrenergic blockade in the Marfan syndrome: experience over 10 years. Am J Med Genet 1989, 32:245.
- Gray JR, Bridges AB, West RR, et al: Life expectancy in British Marfan syndrome populations. Clin Genet 1998, 54:124–128. CrossRef
- Silverman DI, Burton KJ, Gray J, et al: Life expectancy in the Marfan syndrome. Am J Cardiol 1995, 75:157–160. CrossRef
- DePaepe A, Deitz HC, Devereux RB, et al: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62:417–426. CrossRef
- Health supervision for children with Marfan syndrome. American Academy of Pediatrics Committee on Genetics [no authors listed]. Pediatrics 1996, 98:978–982.
- National Marfan Foundation. Available at http://www.marfan.org/nmf/. Accessed April 2006.
- Dean JCS: Management of Marfan syndrome. Heart 2002, 88:97–103. CrossRef
- Roman MJ, Devereux RB, Kramer-Fox R, et al: Twodimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989, 64:507–512. CrossRef
- Loeys BL, Chen J, Neptune ER, et al: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275–281. CrossRef
- Pyeritz RE: The Marfan syndrome. Ann Rev Med 2000, 51:481–510. CrossRef
- Dietz HC, Pyeritz RE: Marfan syndrome and related disorders. In The Metabolic and Molecular Bases of Inherited Disease, edn 8. Edited by Scriver CR, et al. New York: McGraw-Hill; 2000:5287–5311.
- Maron BJ, Chaitman BR, Ackerman MJ, et al: Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807–2816. CrossRef
- Maron BJ: Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005, 45:1340–1345. CrossRef
- Milewicz DM, Dietz HC, Miller DC: Treatment of aortic disease in patients with Marfan Syndrome. Circulation 2005, 111:e150-e157. A concise, thorough review of the Marfan syndrome. The focus is predominantly on the cardiovascular manifestations of Marfan syndrome and their medical and surgical management. CrossRef
- Rossi-Foulkes R, Roman MJ, Rosen SE, et al: Phenotypic features and impact of beta blocker or calcium channel antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999, 83:1364–1368. CrossRef
- Yetman AT, Bornemeier RA, McCrindle BW: Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005, 95:1125–1127. CrossRef
- Dietz HC, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet Part C Semin Med Genet 2005, 139:4–9.
- Judge DP, Dietz HC: Marfan’s syndrome. Lancet 2005, 366:1965–1976. An excellent review of the Marfan syndrome. Additional data include a listing of other syndromes that present with similar phenotypic characteristics to the Marfan syndrome. Also, a discussion of the most current genetic studies leading to potential advances in medical therapeutics is presented. CrossRef
- Kim SY, Martin N, Hsia EC, et al: Management of aortic disease in Marfan syndrome: a decision analysis. Arch Intern Med 2005, 165:749–755. CrossRef
- Davies RR, Goldstein LJ, Coady MA, et al: Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002, 73:17–27; discussion 27–28. CrossRef
- Zehr KJ, Matloobi A, Connolly HM, et al: Surgical management of the aortic root in patients with Marfan syndrome. J Heart Valve Dis 2005, 14:121–128;discussion 128–129.
- Vricella LA, Williams JA, Ravekes WJ, et al: Early experience with valve-sparing aortic root replacement in children. Ann Thorac Surg 2005, 80:1622–1626; discussion 1626–1627. CrossRef
- Pyeritz RE: The Marfan syndrome in childhood: features, natural history and differential diagnosis. Prog Pediatr Cardiol 1996, 5:151–157. CrossRef
- Cardiovascular management of marfan syndrome in the young
Current Treatment Options in Cardiovascular Medicine
Volume 8, Issue 5 , pp 396-402
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Division of Pediatric Cardiology, Washington University School of Medicine, One Children’s Place, 63110, St. Louis, MO, USA